Navigation Links
IDX899 Demonstrates Rapid and Profound Inhibition of HIV Replication in a Phase I/II Clinical Trial in Treatment-Naive HIV-Infected Patients
Date:2/6/2008

le doses up to 800 mg over a seven-day period. No serious adverse events or pattern of laboratory abnormalities were observed. Food enhanced the absorption of IDX899. Additionally, in a single-dose drug-drug interaction study assessing the combination of either 100 or 800 mg IDX899 and 100 mg atazanavir (Reyataz(R)), atazanavir plasma levels were not markedly altered by IDX899.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus and HIV. For further information about Idenix, please refer to http://www.idenix.com.

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward- looking statements can be identified by the use of forward-looking terminology such as "could," "may," "will," or similar expressions, or by express or implied statements with respect to the company's clinical development programs in HIV, or any potential pipeline candidates for the treatment of HIV, including any expressed or implied statement regarding the efficacy and safety of IDX899. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantees that the company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization. In particular, management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
2. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
3. TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkins Lymphoma
4. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
5. Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients
6. Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema
7. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
8. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
9. Large Controlled Trial of Widely Used Mood Stabilizers Demonstrates Efficacy in Pediatric Bipolar Disorder
10. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
11. Research Study Demonstrates Prolonged Benefit of Fitness Program for Bladder Control & Sexual Function in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Research and Markets has ... Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market ... offering. On the basis of ... has been divided into eight major segments, namely, ... hydromechanical ablation technologies. The light/laser ablation technology segment ...
(Date:9/22/2014)... Sept. 22, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ... fiscal 2014 ended July 31, 2014 on Monday, September 29 ... discuss the results at 11:00 AM ET. Participating in the ... Andrew A. Krakauer , President and CEO; Jorgen B. ... Sheldon , Senior Vice President, CFO and Treasurer; and ...
(Date:9/22/2014)... NORTH CHICAGO, Ill. , Sept. 22, 2014 ... that data from several clinical studies evaluating potential ... be presented at the upcoming 2014 European Society ... in Madrid, Spain . Data ... study evaluating the safety and efficacy of veliparib ...
Breaking Medicine Technology:Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - Forecasts to 2019 2Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - Forecasts to 2019 3Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2014 Ended July 31, 2014 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4
... Ad, " This is Medicare and America at ... WASHINGTON, Dec. 9 The SCOOTER Store today launched a ... and cost savings associated with Medicare,s Power Mobility Benefit, which ... to receive power wheelchairs. , With budget cuts likely in ...
... , ROCKVILLE, Md., Dec. 9 Novavax, Inc. (Nasdaq: ... closed its previously announced public offering of 6,800,000 shares of ... net proceeds from the sale of the shares, after underwriting ... which will be used for preclinical studies and clinical trials ...
Cached Medicine Technology:The SCOOTER Store Launches New Advertising Highlighting the Value and Cost Savings From Medicare's Power Mobility Benefit 2NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock 2
(Date:9/22/2014)... News) -- Teens and young adults at risk for ... help prevent risky sexual behaviors, according to new recommendations ... year, about 20 million new sexually transmitted infections such ... About half involve people between 15 and 24 years ... new report, published Sept. 22 in Annals of ...
(Date:9/22/2014)... surprising new study pulls back the curtain on one ... in payment and income between physicians who perform operations, ... Contrary to perception, the research indicates, the physician payment ... other procedure-performing doctors. , The new findings counter the ... per minute explains why doctors who perform procedures often ...
(Date:9/22/2014)... New York, NY (PRWEB) September 22, 2014 ... pain on the side of the hip , ... for hip bursitis treatment in Manhattan. This treatment is now offered ... bursitis, which is also called trochanteric bursitis, occurs when ... is a fluid-filled sac in the hip, between the ...
(Date:9/22/2014)... By Steven Reinberg ... -- Pediatricians are urging that all children aged 6 months ... The American Academy of Pediatrics updated their influenza vaccine recommendations ... doses of vaccine to build immunity. The AAP also wants ... their kids the nasal spray vaccine instead of the flu ...
(Date:9/22/2014)... patients undergoing breast cancer surgery require additional operations because ... in the initial operation. However, researchers at Brigham and ... developed that will help surgeons better distinguish cancerous breast ... repeat operations. , The study is ... the Proceedings of the National Academy of Sciences ...
Breaking Medicine News(10 mins):Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 3Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 2Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 3Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 4Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 2Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 3Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 2Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 3Health News:The fine line between breast cancer and normal tissues 2
... By Randy Dotinga and Steven Reinberg HealthDay Reporters ... into full swing, a new report Wednesday warns that water pollution ... beach. Last year was one of the worst in two ... Gulf of Mexico oil spill and rainy weather, according to ...
... the most common form of ovarian cancer is characterized by ... changes in the genome itself, said members of The Cancer ... Medicine ( www.bcm.edu ) Human Genome Sequencing Center ( ... tumors. The study was the first to achieve an overview ...
... Chicago --- The 4th edition of the Concise Guide ... Hospital,s psychiatrists, Mina Dulcan, MD, and Mary Beth Lake, ... Dulcan is department head of Child and Adolescent Psychiatry ... School of Medicine. Lake is a child psychiatrist at ...
... Aviv Parkinson,s Disease, brought to public awareness by ... difficult to diagnose. It,s also difficult to accurately estimate ... statistics come from small-scale studies, usually based on information ... exist to track how many people have the disease. ...
... scientists at the University of California, San Francisco has developed ... determining the order in which mutations emerge in them as ... invasive, malignant masses. The work may give doctors ... of early cancers, when they are generally more treatable than ...
... at least 116 million adult Americans experience chronic pain, a ... billion annually, says a new report from the Institute of ... be better managed, added the committee that wrote the report. ... of public and private organizations to create a cultural transformation ...
Cached Medicine News:Health News:Pollution Took Heavy Toll at U.S. Beaches in 2010 2Health News:Pollution Took Heavy Toll at U.S. Beaches in 2010 3Health News:Pollution Took Heavy Toll at U.S. Beaches in 2010 4Health News:Sequence of ovarian genome identifies predominant gene mutations, points to possible treatment 2Health News:Sequence of ovarian genome identifies predominant gene mutations, points to possible treatment 3Health News:Sequence of ovarian genome identifies predominant gene mutations, points to possible treatment 4Health News:Latest guide on child and adolescent psychiatry 2Health News:Getting an accurate read on Parkinson's 2Health News:Getting an accurate read on Parkinson's 3Health News:UCSF-led team decodes evolution of skin and ovarian cancer cells 2Health News:IOM report calls for cultural transformation of attitudes toward pain and its prevention and management 2Health News:IOM report calls for cultural transformation of attitudes toward pain and its prevention and management 3
... The new Amsco 3080/3085 SP Bariatric ... width capacity and expanded surgical capabilities for ... extensions are rated for patients up to ... and easy attachment and full positioning capability. ...
... The new Amsco 3080/3085 SP Bariatric Foot ... capacity and expanded surgical capabilities for Amsco ... The Amsco Foot Extension is rated for ... designed for secure and easy attachment and ...
... The Pulsavac Plus System offers a ... Debridement System. High power efficiently clears bone ... Specific tips are available for hip and ... a wide range of pressure options for ...
The Simpulse Solo Pulsed Lavage System requires minimal set up and has a Wide range of tips available for every orthopaedic procedure. It uses a separate suction lumen to reduce clogging and n ergono...
Medicine Products: